TransMedics Group (TMDX) Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TMDX shares.
View TMDX analyst ratings or view top-rated stocks.

7 equities research analysts have issued 1 year target prices for TransMedics Group's stock. Their TMDX share price forecasts range from $45.00 to $90.00. On average, they expect the company's share price to reach $72.29 in the next twelve months. This suggests that the stock has a possible downside of 9.7%.
View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts.

TransMedics Group's stock was trading at $61.72 at the start of the year. Since then, TMDX stock has increased by 29.6% and is now trading at $80.01.
View the best growth stocks for 2023 here.

TransMedics Group saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,300,000 shares, an increase of 35.2% from the April 30th total of 2,440,000 shares. Based on an average daily volume of 635,600 shares, the short-interest ratio is currently 5.2 days.
View TransMedics Group's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our TMDX earnings forecast.

TransMedics Group, Inc. (NASDAQ:TMDX) announced its quarterly earnings data on Monday, May, 1st. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.17. The company had revenue of $41.60 million for the quarter, compared to the consensus estimate of $36.05 million. TransMedics Group had a negative net margin of 23.76% and a negative trailing twelve-month return on equity of 18.30%. The firm's revenue was up 161.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.38) EPS.

ETFs with the largest weight of TransMedics Group (NASDAQ:TMDX) stock in their portfolio include Changebridge Select Equity ETF (CBSE), Changebridge Long/Short Equity ETF (CBLS), Invesco DWA Healthcare Momentum ETF (PTH), Alger 35 ETF (ATFV), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Invesco DWA SmallCap Momentum ETF (DWAS) and Principal Healthcare Innovators ETF (BTEC).

TransMedics Group issued an update on its FY 2023 earnings guidance on Monday, May, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $160.00 million-$170.00 million, compared to the consensus revenue estimate of $157.66 million.

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

(TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

TransMedics Group's stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (10.00%), BlackRock Inc. (6.93%), Macquarie Group Ltd. (5.36%), Fred Alger Management LLC (3.51%), Allspring Global Investments Holdings LLC (2.94%) and Credit Suisse AG (2.53%). Insiders that own company stock include Abrams Capital Management, LP, David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends.

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TMDX stock can currently be purchased for approximately $80.01.

TransMedics Group (NASDAQ:TMDX) has a market capitalization of $2.60 billion and generates $93.46 million in revenue each year. The company earns $-36,230,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

The company employs 148 workers across the globe.

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com.